Stock Financial Ratios, Dividends, Split History

RMP / Rice Midstream Partners LP financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Market Cap ($M)1,838.39
Enterprise Value ($M)2,116.87
Book Value ($M)2,545.66
Book Value / Share24.88
Price / Book0.72
NCAV ($M)-247.58
NCAV / Share-2.42
Price / NCAV-7.43
Share Statistics
Common Shares Outstanding2 28,753,623
Common Shares Outstanding 73,549,485
Scoring Models
Piotroski F-Score1.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)n/a
Return on Assets (ROA)n/a
Return on Equity (ROE)n/a
Balance Sheet (mrq) ($M)
Quick Ration/a
Current Ratio2.91
Income Statement (mra) ($M)
Oil And Gas Revenue0.00
Sales Revenue Net0.00
Revenue From Related Parties0.00
Cash Flow Statement (mra) ($M)
Identifiers and Descriptors
Central Index Key (CIK)1620928
Related CUSIPS
762819950 762819900

Split History

Stock splits are used by Rice Midstream Partners LP to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

8h - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

9h - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Related News Stories

RMP vs. PXD: Which Stock Is the Better Value Option?

2018-06-26 zacks
Investors looking for stocks in the Oil and Gas - Exploration and Production - United States sector might want to consider either Rice Midstream Partners (RMP - Free Report) or Pioneer Natural Resources (PXD - Free Report) . But which of these two stocks offers value investors a better bang for their buck right now? We'll need to take a closer look.

4 Reasons These High-Yield, Hyper Growth Income Stocks Could Make You Rich

2018-06-25 seekingalpha
Thanks to a perfect storm of negative (but temporary) factors, MLPs have spent almost four years in a bear market. (21-0)

Options Traders Expect Huge Moves in Rice Midstream Partners (RMP) Stock

2018-06-19 zacks
Investors in Rice Midstream Partners LP (RMP - Free Report) need to pay close attention to the stock based on moves in the options market lately. That is because the Jul 20, 2018 $30.00 Put had some of the highest implied volatility of all equity options today.

EQT Midstream Partners: To Wait Or Not To Wait

2018-06-18 seekingalpha
My investment club will have its shares of Rice Midstream converted to EQT Midstream in the third quarter of 2018. (8-0)

Master Limited Partnership Simplifications On The Rise

2018-05-18 seekingalpha
The three only mark an acceleration of the trend of MLP "roll-ups," however. Many others have been announced in 2018. (43-0)

CUSIP: 762819100